{
    "title": "CHLOROBIS COPPER (I) COMPLEX COMPOSITIONS AND METHODS OF MANUFACTURE AND USE",
    "inventor_name": "Charles Louis Charles Barker",
    "publication_year": 2015,
    "device_name": "Copper-1 (Anhydrous copper complex C12H10ClCuN2O4)",
    "goal": "Provide a pharmaceutical or dietary-supplement composition to treat neuromuscular and other diseases, including Lyme disease.",
    "problem_addressed": "Neuromuscular degeneration, chronic inflammation, infectious diseases such as Lyme disease, and a broad list of disorders (fibromyalgia, MS, RA, Alzheimer's, etc.).",
    "concept_summary": "The invention describes an anhydrous copper complex (C12H10ClCuN2O4) that can be administered orally or pharmaceutically to alleviate symptoms of many neuromuscular and infectious diseases. The copper complex is claimed to have anti-inflammatory, antimicrobial, and neuro-protective properties.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Copper-based antimicrobial activity",
        "Anti-inflammatory chemical action",
        "Neuro-protective effects of copper ions"
    ],
    "scientific_domains": [
        "Pharmacology",
        "Medicine",
        "Chemistry"
    ],
    "mechanisms_of_action": [
        "Copper ion disrupts bacterial metabolism",
        "Modulation of inflammatory pathways",
        "Support of mitochondrial function in muscle cells"
    ],
    "materials": [
        "Copper(I) chloride",
        "Organic ligand (C12H10ClCuN2O4)",
        "Excipient compounds (e.g., diluents, binders)"
    ],
    "energy_sources": [],
    "inputs": [
        "C12H10ClCuN2O4 compound (active ingredient)",
        "Patient (subject) requiring treatment"
    ],
    "outputs": [
        "Reduced disease symptoms",
        "Improved neuromuscular function",
        "Decreased bacterial load (for Lyme disease)"
    ],
    "claimed_performance": "The composition is claimed to treat or reduce symptoms of a wide range of diseases, including Lyme disease, fibromyalgia, multiple sclerosis, rheumatoid arthritis, Alzheimer's, and many others.",
    "experimental_evidence": "SEM images and mass-spectrometry data (Figures 1-9) confirm the chemical structure of the copper complex; no clinical trial data are presented.",
    "replication_status": null,
    "keywords": [
        "Copper-1",
        "C12H10ClCuN2O4",
        "Lyme disease",
        "Neuromuscular disease",
        "Dietary supplement",
        "Pharmaceutical"
    ],
    "related_technologies": [
        "Copper supplementation",
        "Antimicrobial metal complexes",
        "Nutraceuticals"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.9,
    "practicability_score": 0.6,
    "fringe_score": 0.4,
    "evidence_strength": 0.2,
    "risk_score": 0.3,
    "trl_estimate": 4,
    "source_urls": [
        "http://www.rexersearch.com",
        "https://mitocopper.com",
        "https://vimeo.com/348475547"
    ],
    "organizations": [
        "Lab Pharma International"
    ],
    "applications": [
        "Treatment of Lyme disease",
        "Management of neuromuscular disorders",
        "Adjunct therapy for inflammatory conditions"
    ],
    "limitations": [
        "No peer-reviewed clinical data provided",
        "Regulatory approval status unknown",
        "Dosage and safety profile not fully described"
    ],
    "open_questions": [
        "What is the clinical efficacy in human trials?",
        "Are there any long-term toxicity concerns with chronic copper exposure?",
        "How does the compound interact with existing medications?"
    ],
    "red_flags": [
        "Claims of broad therapeutic benefit without clinical evidence",
        "Potential for copper toxicity if mis-dosed"
    ],
    "evidence_quotes": [
        "The present invention is directed to pharmaceutical and/or dietary supplement compositions and methods of treating neuromuscular and other diseases...",
        "The pharmacologically active ingredient of the present invention possesses the following chemical structure, referred to herein as Formula I:",
        "FIG. 1 depicts imagery obtained from Scanning Electron Microscope (SEM) analysis of a preferred embodiment of the present invention.",
        "FIG. 3 shows the quantitative results obtained by mass spectrometry analysis of a preferred embodiment of the composition of the invention.",
        "The objective of the present invention is to provide pharmaceutical and/or dietary supplement compositions and methods of making and using the same to treat and reduce many of the symptoms of several diseases."
    ]
}